a unique platform to mass produce antibodies for immunotherapy

Plant-based Antibodies

Our vision is to produce safer, efficient, and cheaper antibodies for human consumption. We believe that the next generation of medicine should be efficient, affordable, and minimal side effects.

/ 01

mission

Plant-based antibodies

Plantibodies is a unique plant-based platform to mass produce antibodies for immunotherapy. We intend on developing the next generation of medical treatment to cure life threatening and terminal diseases.

Antibodies produced on our platform are intended for human consumption in immunotherapy against cancers, neurodegenerative diseases, and autoimmune diseases.

The number of patients who suffer from life threatening and incurable diseases such as cancer, neurodegenerative diseases, and pathogenic infections is rising steadily. For example, in the USA over 1.7 million people diagnosed with cancer each year, costing over $147 billion dollars (2017), and 5.4 million people are diagnosed with Alzhimers and Parkinsons globally (2016). These patients have no efficient treatment for these diseases. Or the treatments are expensive, unsafe (chemotherapy), and have excessive side effects.

Our aim is to help these patients manage their disease by boosting their own lymphocytes. We would reduce painful side effects, while removing the disease from their bodies.

We intend to develop antibodies against these terminal diseases to stimulate the patient’s own immune system. The stimulated immune system would attack the diseased cells and phagocytes them from the body. A naturally occurring process enhanced by our antibodies.

/ 02

Technology

cheaper, safer, and more stable antibodies

At Plantibodies we combine the latest advances in synthetic and molecular biology produce antibodies. We strive to develop a unique and a cutting edge biotechnology platform to produce antibodies. Our antibodies are mass produced, vertebrate pathogen free, and more stable than our competitors.

Our products are intended to cure terminal diseases such as cancer, neurodegenerative diseases, and autoimmune diseases. We employ the latest technologies in synthetic biology and plant science to produce life saving antibodies for immunotherapy. We believe in deploying the patient’s own immune system, aided by our antibodies to fight diseases. Our antibodies will boost the patient’s lymphocyte system (B-cells and T-cell) to improve detecting and phagocytosis diseased cells.

/ 03

team

Highly qualified and innovation driven

From France’s top research bioscience institutions as well as business schools, this team has coalesced around the vision and the talents of Bilal Mazhar of creating plant-based antibodies that urgently need to be released onto the market on a mass scale, especially in developing countries. 

Pierre BAUËR, Co-founder -CEO

Broadly trained in science (Engineer, PhD) and business (MBA)

BILAL MAZHAR, co-founder -cso

Chief Scientific Officer (CSO) of Plantibodies as well as its visionary.

Jessica APULEI, Co-founder - CTO

PhD in neuroscience and pathology at College de France (2019).

Won KIM, co-founder -advisor

PHD and MBA, full-time professor at ESCE, Paris business school.

en_USEnglish
fr_FRFrench en_USEnglish